Cyclooxygenase-2 in human non-small cell lung cancer

Hsin Yuan Fang, T. S. Lin, J. P. Lin, Y. C. Wu, K. C. Chow, L. S. Wang

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Aim: Recent studies report that the expression of cyclooxygenase (COX) in non-small cell lung cancer (NSCLC) is increased, especially in adenocarcinoma. Platelet activating factor (PAF), n-sodium butyrate (n-BT), and phorbol myristate acetate (PMA) are important mediators of the inflammatory process. Method: Expression of COX-2 in 67 stage 1 NSCLC paraffin-embedded tumor samples was determined by immunohistochemistry (IHC). Four NSCL cell lines were incubated and stimulated by PAF, n-BT and PMA for 48 h. Expression of COX-2 was determined by IHC, immunoblotting, and reverse transcription-polymerase chain reaction (RT-PCR). Result: IHC showed increasing immunoreactivity in 35 of 67 (52%) in stage 1 NSCLC, 31 of 53 (59%) in adenocarcinoma and 13 of 15 (87%) in bronchoalveolar cell carcinoma, but only 2 of 12 (17%) in epidermoid carcinoma. The COX-2 expression in NSCLC cells was 75% (3/4) and the COX-1 expression in NSCLC cells was 100% (4/4). After stimulation with PMA, n-BT, PAF and n-BT + PAF, the COX-2 expression in NSCLC cells was significantly increased in all cell lines. Conclusions: The expression of COX-2 in NSCLC cells is high and was up-regulated by PMA, n-BT and PAF. We consider that COX-2 inhibitors will play an important role in the therapy of NSCLC.

Original languageEnglish
Pages (from-to)171-177
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume29
Issue number2
DOIs
Publication statusPublished - Mar 2003
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Non-Small Cell Lung Carcinoma
Butyric Acid
Butyrates
Platelet Activating Factor
Tetradecanoylphorbol Acetate
Immunohistochemistry
Adenocarcinoma
Cell Line
Cyclooxygenase 1
Cyclooxygenase 2 Inhibitors
Prostaglandin-Endoperoxide Synthases
Immunoblotting
Paraffin
Reverse Transcription
Squamous Cell Carcinoma
Carcinoma
Polymerase Chain Reaction

Keywords

  • Cyclooxygenase
  • Lung cancer
  • Prostaglandin

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Fang, H. Y., Lin, T. S., Lin, J. P., Wu, Y. C., Chow, K. C., & Wang, L. S. (2003). Cyclooxygenase-2 in human non-small cell lung cancer. European Journal of Surgical Oncology, 29(2), 171-177. https://doi.org/10.1053/ejso.2002.1316

Cyclooxygenase-2 in human non-small cell lung cancer. / Fang, Hsin Yuan; Lin, T. S.; Lin, J. P.; Wu, Y. C.; Chow, K. C.; Wang, L. S.

In: European Journal of Surgical Oncology, Vol. 29, No. 2, 03.2003, p. 171-177.

Research output: Contribution to journalArticle

Fang, HY, Lin, TS, Lin, JP, Wu, YC, Chow, KC & Wang, LS 2003, 'Cyclooxygenase-2 in human non-small cell lung cancer', European Journal of Surgical Oncology, vol. 29, no. 2, pp. 171-177. https://doi.org/10.1053/ejso.2002.1316
Fang, Hsin Yuan ; Lin, T. S. ; Lin, J. P. ; Wu, Y. C. ; Chow, K. C. ; Wang, L. S. / Cyclooxygenase-2 in human non-small cell lung cancer. In: European Journal of Surgical Oncology. 2003 ; Vol. 29, No. 2. pp. 171-177.
@article{4a76ce3c08c54749b83108d204914e94,
title = "Cyclooxygenase-2 in human non-small cell lung cancer",
abstract = "Aim: Recent studies report that the expression of cyclooxygenase (COX) in non-small cell lung cancer (NSCLC) is increased, especially in adenocarcinoma. Platelet activating factor (PAF), n-sodium butyrate (n-BT), and phorbol myristate acetate (PMA) are important mediators of the inflammatory process. Method: Expression of COX-2 in 67 stage 1 NSCLC paraffin-embedded tumor samples was determined by immunohistochemistry (IHC). Four NSCL cell lines were incubated and stimulated by PAF, n-BT and PMA for 48 h. Expression of COX-2 was determined by IHC, immunoblotting, and reverse transcription-polymerase chain reaction (RT-PCR). Result: IHC showed increasing immunoreactivity in 35 of 67 (52{\%}) in stage 1 NSCLC, 31 of 53 (59{\%}) in adenocarcinoma and 13 of 15 (87{\%}) in bronchoalveolar cell carcinoma, but only 2 of 12 (17{\%}) in epidermoid carcinoma. The COX-2 expression in NSCLC cells was 75{\%} (3/4) and the COX-1 expression in NSCLC cells was 100{\%} (4/4). After stimulation with PMA, n-BT, PAF and n-BT + PAF, the COX-2 expression in NSCLC cells was significantly increased in all cell lines. Conclusions: The expression of COX-2 in NSCLC cells is high and was up-regulated by PMA, n-BT and PAF. We consider that COX-2 inhibitors will play an important role in the therapy of NSCLC.",
keywords = "Cyclooxygenase, Lung cancer, Prostaglandin",
author = "Fang, {Hsin Yuan} and Lin, {T. S.} and Lin, {J. P.} and Wu, {Y. C.} and Chow, {K. C.} and Wang, {L. S.}",
year = "2003",
month = "3",
doi = "10.1053/ejso.2002.1316",
language = "English",
volume = "29",
pages = "171--177",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Cyclooxygenase-2 in human non-small cell lung cancer

AU - Fang, Hsin Yuan

AU - Lin, T. S.

AU - Lin, J. P.

AU - Wu, Y. C.

AU - Chow, K. C.

AU - Wang, L. S.

PY - 2003/3

Y1 - 2003/3

N2 - Aim: Recent studies report that the expression of cyclooxygenase (COX) in non-small cell lung cancer (NSCLC) is increased, especially in adenocarcinoma. Platelet activating factor (PAF), n-sodium butyrate (n-BT), and phorbol myristate acetate (PMA) are important mediators of the inflammatory process. Method: Expression of COX-2 in 67 stage 1 NSCLC paraffin-embedded tumor samples was determined by immunohistochemistry (IHC). Four NSCL cell lines were incubated and stimulated by PAF, n-BT and PMA for 48 h. Expression of COX-2 was determined by IHC, immunoblotting, and reverse transcription-polymerase chain reaction (RT-PCR). Result: IHC showed increasing immunoreactivity in 35 of 67 (52%) in stage 1 NSCLC, 31 of 53 (59%) in adenocarcinoma and 13 of 15 (87%) in bronchoalveolar cell carcinoma, but only 2 of 12 (17%) in epidermoid carcinoma. The COX-2 expression in NSCLC cells was 75% (3/4) and the COX-1 expression in NSCLC cells was 100% (4/4). After stimulation with PMA, n-BT, PAF and n-BT + PAF, the COX-2 expression in NSCLC cells was significantly increased in all cell lines. Conclusions: The expression of COX-2 in NSCLC cells is high and was up-regulated by PMA, n-BT and PAF. We consider that COX-2 inhibitors will play an important role in the therapy of NSCLC.

AB - Aim: Recent studies report that the expression of cyclooxygenase (COX) in non-small cell lung cancer (NSCLC) is increased, especially in adenocarcinoma. Platelet activating factor (PAF), n-sodium butyrate (n-BT), and phorbol myristate acetate (PMA) are important mediators of the inflammatory process. Method: Expression of COX-2 in 67 stage 1 NSCLC paraffin-embedded tumor samples was determined by immunohistochemistry (IHC). Four NSCL cell lines were incubated and stimulated by PAF, n-BT and PMA for 48 h. Expression of COX-2 was determined by IHC, immunoblotting, and reverse transcription-polymerase chain reaction (RT-PCR). Result: IHC showed increasing immunoreactivity in 35 of 67 (52%) in stage 1 NSCLC, 31 of 53 (59%) in adenocarcinoma and 13 of 15 (87%) in bronchoalveolar cell carcinoma, but only 2 of 12 (17%) in epidermoid carcinoma. The COX-2 expression in NSCLC cells was 75% (3/4) and the COX-1 expression in NSCLC cells was 100% (4/4). After stimulation with PMA, n-BT, PAF and n-BT + PAF, the COX-2 expression in NSCLC cells was significantly increased in all cell lines. Conclusions: The expression of COX-2 in NSCLC cells is high and was up-regulated by PMA, n-BT and PAF. We consider that COX-2 inhibitors will play an important role in the therapy of NSCLC.

KW - Cyclooxygenase

KW - Lung cancer

KW - Prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=0037348463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037348463&partnerID=8YFLogxK

U2 - 10.1053/ejso.2002.1316

DO - 10.1053/ejso.2002.1316

M3 - Article

C2 - 12633561

AN - SCOPUS:0037348463

VL - 29

SP - 171

EP - 177

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 2

ER -